Portland, OR -- (SBWIRE) -- 07/25/2017 -- Increase in Abbreviated New Drug Applications (ANDA) over the past years has fostered the demand for API market. Furthermore, Indian companies making increased entries related to Drug Master File (DMF) indicates APIs market gaining traction. Stringent regulatory policies in the European Union is likely to restrain market growth. Patent expiry of biological drugs creates new growth opportunities for key API manufacturers.

"Early Buyers Will Receive 20% Customization on This Report."

The Active Pharmaceutical Ingredient (API) Market segments on the basis of synthesis, type of manufacturer, type and therapy. Based on synthesis, this market is segmented into synthetic API and biotech API. The former is further segmented into Innovative synthetic APIS and generic synthetic APIS, while the latter is further segmented on the basis of products and type. The biotech APIS market, by product is further segmented into monoclonal antibodies, recombinant proteins and vaccines. On the basis of type of manufacturer, this market is segmented into captive API manufacturers, merchant API manufacturers, innovative APIS and generic APIS. On the basis of type, the market is segmented into innovative APIS segment and generic APIS segment. On the basis of therapy, the market is segmented into oncology, diabetes, cardiovascular disease, Cns and neurological disorders, orthopedic disorders, nephrology, ophthalmology, pulmonology, gastrointestinal disorders and endocrinology.

Get PDF Brochure @ https://www.alliedmarketresearch.com/request-toc-and-sample/994

On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific, and Latin America, Middle East & Africa (LAMEA).

Key market players in this market are Teva Pharmaceutical Industries Limited, Dr. Reddys Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Novartis International AG, Albemarle Corporation, Sigma-Aldrich Corporation, Mylan Inc., and Allergan PLC